demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small cell lung cancer (SCLC). Details of the study have been published in the ...

Molecular imaging, including somatostatin receptor scintigraphy but more so PET with specific tracers, such as C 11-5HTP or Ga 68-DOTA octreotate, will improve staging and follow-up of therapy in ...

The following is a summary of "A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors ...

However, the researchers hypothesized that the cone snail’s version of somatostatin, Consomatin G1, might also selectively target the hormone-regulating receptor SSTR 2 due to its structural ...

Because pituitary corticotroph adenomas express somatostatin receptors, somatostatin analogues have been investigated as a potential targeted therapy for the treatment of Cushing's disease.

Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced ...

Lead asset Paltusotine is an oral, selective, non-peptide, somatostatin receptor type 2 (SST2) agonist. An alternative to injectable broad spectrum somatostatin analogs, paltusotine is a non ...

The company’s products include SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2; developing SAR ...

Perspective Therapeutics, Inc.’s CATX share price has dipped by 5.02%, which has investors questioning if this is right time ...

at baseline with first-generation somatostatin receptor ligands (SRLs), octreotide and lanreotide. The safety profile of CAM2029 was consistent with SoC with no new findings.2,3 CAM2029 is ...